Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Axon earnings are due this afternoon. The bar has been lowered for the Taser maker after Axon stock plunged in recent days.

The wirehouse's "strong investment in technology and AI has improved financial advisor productivity," KBW's David Konrad said ...

Leerink raised the firm’s price target on Hims & Hers to $40 from $24 and keeps a Market Perform rating on the shares following the Q4 ...

Chegg faces challenges from Google AI, impacting traffic and revenue. Learn how Chegg plans to innovate with AI tools and ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...

The report raised fears about the sustainability of AI infrastructure growth. That could mean less demand for Nvidia's chips. TD Cowen's Michael Elias said his team's finding points to "a potential ...

Valued at a market cap of $17.7 billion, Ulta Beauty, Inc. (ULTA) is a leading beauty retailer in the United States, offering ...